35445-32-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1,4-dimethyl-5-carbethoxyimidazole is used as a building block in the synthesis of pharmaceuticals and agrochemicals for its versatile chemical properties that facilitate the creation of a wide range of compounds with potential therapeutic and pesticidal effects.
Used in Dye and Pigment Production:
1,4-dimethyl-5-carbethoxyimidazole is utilized as an intermediate in the production of dyes and pigments due to its ability to contribute to the color and stability of these products.
Used in Anti-cancer Research:
1,4-dimethyl-5-carbethoxyimidazole is studied as a potential anti-cancer agent, given its capacity to interact with biological systems in ways that may inhibit or reduce the growth of cancer cells.
Used in Anti-inflammatory Applications:
As a compound with potential anti-inflammatory properties, 1,4-dimethyl-5-carbethoxyimidazole is explored for its use in mitigating inflammation, which could be beneficial in treating various inflammatory conditions.
Used in Antimicrobial and Anti-fungal Agents Development:
1,4-dimethyl-5-carbethoxyimidazole is employed in the development of antimicrobial and anti-fungal agents due to its demonstrated anti-microbial and anti-fungal properties, offering a potential solution for combating infections caused by various pathogens.
Overall, 1,4-dimethyl-5-carbethoxyimidazole's multifaceted utility underscores its importance in chemical and biological research, with ongoing investigations aimed at harnessing its full potential for the betterment of human health and industrial applications.

Upstream product

• 51605-32-4 Ethyl 5-Methyl-4-imidazolecarboxylate 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 51605-32-4 ethyl 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxylate 

Downstream Products

• 113444-43-2 ethyl 2-bromo-1,4-dimethyl-1H-imidazole-5-carboxylate 
• 1094342-63-8 3-chloro-5-[(6-chloro-3-{[5-(1,4-dimethyl-1H-imidazol-5-yl)-1,3,4-oxadiazol-2-yl]methyl}-2-fluorophenyl)oxy]benzonitrile 
• 1094346-39-0 1,4-dimethyl-1H-imidazole-5-carbohydrazide 
• 78449-67-9 3,5-dimethyl-3H-imidazole-4-carboxylic acid 

Relevant academic research and scientific papers

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human

The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

Tetrahydropyranyl Benzamide Derivatives

The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Synthesis and structure-activity relationships of new (5R,8R,10R)-ergoline derivatives with antihypertensive or dopaminergic activity

A series of new (5R,8R,10R)-ergoline derivatives was synthesized, and their antihypertensive and dopaminergic activities were tested in conscious spontaneously hypertensive rats and in rats with unilateral 6- hydroxydopamine-induced lesions of the substantia nigra. (5R,8R,10R)-6- Alkyl-8-ergolinemethanols, prepared from the corresponding ergolinecarboxylates, were converted to the tosylates, which were treated with various five-membered heterocycles containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18- fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4- Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active than bromocriptine mesylate and pergolide mesylate, respectively. Several compounds exhibited potent antihypertensive activity. Structure- activity relationships for antihypertensive and dopaminergic activities are discussed.